Literature DB >> 9606228

Incidence and prevalence of neutralizing antibodies to the common adenoviruses in children with cystic fibrosis: implication for gene therapy with adenovirus vectors.

P A Piedra1, G A Poveda, B Ramsey, K McCoy, P W Hiatt.   

Abstract

OBJECTIVE: Defining the infection rate and prevalence of the common adenoviruses (Ads) in cystic fibrosis (CF) children may aid in formulation of strategies for gene therapy with Ad vectors. We undertook this study to determine the incidence and prevalence of infection with the common Ads in children with CF.
METHODOLOGY: Thirty newly diagnosed CF children mean age 1.1 years (Group 1), 48 CF children mean age 4.6 years (Group 2), and 47 mothers of CF children (Group 3) were followed for a mean of 13 months. Group 4 consisted of 33 adult volunteers seen once. Throat and stool specimens for virus culture, and blood samples were obtained every 3 months from CF children in Group 1. Blood samples from CF children (Group 2) and their mothers (Group 3) were obtained every 6 months, and once from adults in Group 4. Neutralizing antibody to Ad serotypes 1 through 7 (Ad 1 to Ad 7) was evaluated with a microneutralization assay.
RESULTS: Five (16.7%) CF children in Group 1 were culture-positive for an Ad; 4 of these CF children developed a fourfold or greater rise in antibody titer. Ad 3 infection occurred frequently based on serology; seronegative (< 3.5 log 2) CF children had a higher infection rate compared with seropositive CF children (7/11 vs 1/34). The prevalence of neutralizing antibodies in CF children in order of decreasing frequency was 91.1% to Ad 3, 37.5% to Ad 2, 27.1% to Ad 1, 26.1% to Ad 7, 16.7% to Ad 5, 8.5% to Ad 4, and 2.0% to Ad 6. The neutralizing antibody titers in seropositive CF children were comparable to those in adults except to Ad 3, which was significantly greater in mothers of CF children.
CONCLUSIONS: CF children had a normal antibody response after Ad infection, preexisting antibody may protect against reinfection and antibody prevalence was low to the common Ads.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9606228     DOI: 10.1542/peds.101.6.1013

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  44 in total

1.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.

Authors:  D Maione; C Della Rocca; P Giannetti; R D'Arrigo; L Liberatoscioli; L L Franlin; V Sandig; G Ciliberto; N La Monica; R Savino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

2.  Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors.

Authors:  Mieke C Sprangers; Wandena Lakhai; Wouter Koudstaal; Marielle Verhoeven; Björn F Koel; Ronald Vogels; Jaap Goudsmit; Menzo J E Havenga; Stefan Kostense
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

Review 3.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

4.  Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer.

Authors:  E J Kremer; S Boutin; M Chillon; O Danos
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 5.  Genetic medicine strategies to protect against bioterrorism.

Authors:  Julie L Boyer; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

6.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

7.  A myristoylated alanine-rich C kinase substrate-related peptide suppresses cytokine mRNA and protein expression in LPS-activated canine neutrophils.

Authors:  Jingjing Li; Melissa A D'Annibale-Tolhurst; Kenneth B Adler; Shijing Fang; Qui Yin; Adam J Birkenheuer; Michael G Levy; Samuel L Jones; Eui Jae Sung; Eleanor C Hawkins; Jeffrey A Yoder; Shila K Nordone
Journal:  Am J Respir Cell Mol Biol       Date:  2012-12-06       Impact factor: 6.914

8.  Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.

Authors:  K Tominaga; S Kuriyama; H Yoshiji; A Deguchi; Y Kita; F Funakoshi; T Masaki; K Kurokohchi; N Uchida; T Tsujimoto; H Fukui
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Bharti P Nehete; Stephanie J Buchl; Donna Palmer; David C Montefiori; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  Viruses       Date:  2009-12-01       Impact factor: 5.048

10.  Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines.

Authors:  Eric A Weaver; Pramod N Nehete; Stephanie S Buchl; Julien S Senac; Donna Palmer; Philip Ng; K Jagannadha Sastry; Michael A Barry
Journal:  PLoS One       Date:  2009-03-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.